Cargando…
Non-Pegylated Liposomal Doxorubicin-Cyclophosphamide in Sequential Regimens with Taxanes as Neoadjuvant Chemotherapy in Breast Cancer Patients
Purpose: Chemotherapy regimens containing anthracyclines and taxanes represent the landmark of neoadjuvant systemic therapy of breast cancer. In advanced breast cancer patients liposomal anthracyclines (LA) have shown similar efficacy and less cardiac toxicity when compared to conventional anthracyc...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4026993/ https://www.ncbi.nlm.nih.gov/pubmed/24847380 http://dx.doi.org/10.7150/jca.9132 |
_version_ | 1782316931784638464 |
---|---|
author | Vici, Patrizia Pizzuti, Laura Gamucci, Teresa Sergi, Domenico Conti, Francesca Zampa, Germano Del Medico, Pietro De Vita, Roy Pozzi, Marcello Botti, Claudio Di Filippo, Simona Tomao, Federica Sperduti, Isabella Di Lauro, Luigi |
author_facet | Vici, Patrizia Pizzuti, Laura Gamucci, Teresa Sergi, Domenico Conti, Francesca Zampa, Germano Del Medico, Pietro De Vita, Roy Pozzi, Marcello Botti, Claudio Di Filippo, Simona Tomao, Federica Sperduti, Isabella Di Lauro, Luigi |
author_sort | Vici, Patrizia |
collection | PubMed |
description | Purpose: Chemotherapy regimens containing anthracyclines and taxanes represent the landmark of neoadjuvant systemic therapy of breast cancer. In advanced breast cancer patients liposomal anthracyclines (LA) have shown similar efficacy and less cardiac toxicity when compared to conventional anthracyclines. We performed this retrospective analysis in order to evaluate the efficacy and tolerability of neoadjuvant regimens including LA outside of clinical trials in routine clinical practice. Methods: Fifty operable or locally advanced, HER2 negative, breast cancer patients were retrospectively identified in 5 Italian cancer centres. Nineteen patients had received 4 cycles of non-pegylated liposomal doxorubicin (NPLD) and cyclophosphamide, followed by 4 cycles of docetaxel, every 3 weeks. In 25 patients the reverse sequence was employed, and a third subgroup of 6 patients received 4 cycles of NPLD/cyclophosphamide every 3 weeks followed by 4 cycles of weekly carboplatin and paclitaxel. Results: We observed 10 pathological complete responses (pCR) (20.0%, 95%CI, 9% to 31%), and 35 (70%, 95%CI, 57.3% to 82.7%) partial responses (pPR), whereas no patients progressed onto therapy. In the small subset of triple negative tumors the pCR rate was 37.5%, and in tumors expressing ER and/or PgR it was 16.7%. A pCR rate of 26.5% was observed in tumors with high Ki-67, whereas in tumors with low Ki-67 only one (6.2%) pCR was observed (p=0.14). Treatments were well tolerated. The most common toxicities were myelosuppression and palmar-plantar erytrodysesthesia; 4 asymptomatic and transient LVEF decrease have been recorded, without any case of clinical cardiotoxicity. Conclusions: NPLD-cyclophosphamide and taxanes sequential regimens were proven effective and well tolerated in breast cancer patients with contra-indication to conventional anthracyclines undergoing neoadjuvant chemotherapy, even outside of clinical trials in everyday clinical practice. |
format | Online Article Text |
id | pubmed-4026993 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-40269932014-05-20 Non-Pegylated Liposomal Doxorubicin-Cyclophosphamide in Sequential Regimens with Taxanes as Neoadjuvant Chemotherapy in Breast Cancer Patients Vici, Patrizia Pizzuti, Laura Gamucci, Teresa Sergi, Domenico Conti, Francesca Zampa, Germano Del Medico, Pietro De Vita, Roy Pozzi, Marcello Botti, Claudio Di Filippo, Simona Tomao, Federica Sperduti, Isabella Di Lauro, Luigi J Cancer Research Paper Purpose: Chemotherapy regimens containing anthracyclines and taxanes represent the landmark of neoadjuvant systemic therapy of breast cancer. In advanced breast cancer patients liposomal anthracyclines (LA) have shown similar efficacy and less cardiac toxicity when compared to conventional anthracyclines. We performed this retrospective analysis in order to evaluate the efficacy and tolerability of neoadjuvant regimens including LA outside of clinical trials in routine clinical practice. Methods: Fifty operable or locally advanced, HER2 negative, breast cancer patients were retrospectively identified in 5 Italian cancer centres. Nineteen patients had received 4 cycles of non-pegylated liposomal doxorubicin (NPLD) and cyclophosphamide, followed by 4 cycles of docetaxel, every 3 weeks. In 25 patients the reverse sequence was employed, and a third subgroup of 6 patients received 4 cycles of NPLD/cyclophosphamide every 3 weeks followed by 4 cycles of weekly carboplatin and paclitaxel. Results: We observed 10 pathological complete responses (pCR) (20.0%, 95%CI, 9% to 31%), and 35 (70%, 95%CI, 57.3% to 82.7%) partial responses (pPR), whereas no patients progressed onto therapy. In the small subset of triple negative tumors the pCR rate was 37.5%, and in tumors expressing ER and/or PgR it was 16.7%. A pCR rate of 26.5% was observed in tumors with high Ki-67, whereas in tumors with low Ki-67 only one (6.2%) pCR was observed (p=0.14). Treatments were well tolerated. The most common toxicities were myelosuppression and palmar-plantar erytrodysesthesia; 4 asymptomatic and transient LVEF decrease have been recorded, without any case of clinical cardiotoxicity. Conclusions: NPLD-cyclophosphamide and taxanes sequential regimens were proven effective and well tolerated in breast cancer patients with contra-indication to conventional anthracyclines undergoing neoadjuvant chemotherapy, even outside of clinical trials in everyday clinical practice. Ivyspring International Publisher 2014-04-25 /pmc/articles/PMC4026993/ /pubmed/24847380 http://dx.doi.org/10.7150/jca.9132 Text en © Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. |
spellingShingle | Research Paper Vici, Patrizia Pizzuti, Laura Gamucci, Teresa Sergi, Domenico Conti, Francesca Zampa, Germano Del Medico, Pietro De Vita, Roy Pozzi, Marcello Botti, Claudio Di Filippo, Simona Tomao, Federica Sperduti, Isabella Di Lauro, Luigi Non-Pegylated Liposomal Doxorubicin-Cyclophosphamide in Sequential Regimens with Taxanes as Neoadjuvant Chemotherapy in Breast Cancer Patients |
title | Non-Pegylated Liposomal Doxorubicin-Cyclophosphamide in Sequential Regimens with Taxanes as Neoadjuvant Chemotherapy in Breast Cancer Patients |
title_full | Non-Pegylated Liposomal Doxorubicin-Cyclophosphamide in Sequential Regimens with Taxanes as Neoadjuvant Chemotherapy in Breast Cancer Patients |
title_fullStr | Non-Pegylated Liposomal Doxorubicin-Cyclophosphamide in Sequential Regimens with Taxanes as Neoadjuvant Chemotherapy in Breast Cancer Patients |
title_full_unstemmed | Non-Pegylated Liposomal Doxorubicin-Cyclophosphamide in Sequential Regimens with Taxanes as Neoadjuvant Chemotherapy in Breast Cancer Patients |
title_short | Non-Pegylated Liposomal Doxorubicin-Cyclophosphamide in Sequential Regimens with Taxanes as Neoadjuvant Chemotherapy in Breast Cancer Patients |
title_sort | non-pegylated liposomal doxorubicin-cyclophosphamide in sequential regimens with taxanes as neoadjuvant chemotherapy in breast cancer patients |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4026993/ https://www.ncbi.nlm.nih.gov/pubmed/24847380 http://dx.doi.org/10.7150/jca.9132 |
work_keys_str_mv | AT vicipatrizia nonpegylatedliposomaldoxorubicincyclophosphamideinsequentialregimenswithtaxanesasneoadjuvantchemotherapyinbreastcancerpatients AT pizzutilaura nonpegylatedliposomaldoxorubicincyclophosphamideinsequentialregimenswithtaxanesasneoadjuvantchemotherapyinbreastcancerpatients AT gamucciteresa nonpegylatedliposomaldoxorubicincyclophosphamideinsequentialregimenswithtaxanesasneoadjuvantchemotherapyinbreastcancerpatients AT sergidomenico nonpegylatedliposomaldoxorubicincyclophosphamideinsequentialregimenswithtaxanesasneoadjuvantchemotherapyinbreastcancerpatients AT contifrancesca nonpegylatedliposomaldoxorubicincyclophosphamideinsequentialregimenswithtaxanesasneoadjuvantchemotherapyinbreastcancerpatients AT zampagermano nonpegylatedliposomaldoxorubicincyclophosphamideinsequentialregimenswithtaxanesasneoadjuvantchemotherapyinbreastcancerpatients AT delmedicopietro nonpegylatedliposomaldoxorubicincyclophosphamideinsequentialregimenswithtaxanesasneoadjuvantchemotherapyinbreastcancerpatients AT devitaroy nonpegylatedliposomaldoxorubicincyclophosphamideinsequentialregimenswithtaxanesasneoadjuvantchemotherapyinbreastcancerpatients AT pozzimarcello nonpegylatedliposomaldoxorubicincyclophosphamideinsequentialregimenswithtaxanesasneoadjuvantchemotherapyinbreastcancerpatients AT botticlaudio nonpegylatedliposomaldoxorubicincyclophosphamideinsequentialregimenswithtaxanesasneoadjuvantchemotherapyinbreastcancerpatients AT difilipposimona nonpegylatedliposomaldoxorubicincyclophosphamideinsequentialregimenswithtaxanesasneoadjuvantchemotherapyinbreastcancerpatients AT tomaofederica nonpegylatedliposomaldoxorubicincyclophosphamideinsequentialregimenswithtaxanesasneoadjuvantchemotherapyinbreastcancerpatients AT sperdutiisabella nonpegylatedliposomaldoxorubicincyclophosphamideinsequentialregimenswithtaxanesasneoadjuvantchemotherapyinbreastcancerpatients AT dilauroluigi nonpegylatedliposomaldoxorubicincyclophosphamideinsequentialregimenswithtaxanesasneoadjuvantchemotherapyinbreastcancerpatients |